A clinical study of inclisiran in patients with homozygous familial hypercholesterolemia

Trial Profile

A clinical study of inclisiran in patients with homozygous familial hypercholesterolemia

Planning
Phase of Trial: Phase III

Latest Information Update: 06 Nov 2017

At a glance

  • Drugs Inclisiran (Primary)
  • Indications Hypercholesterolaemia
  • Focus Registrational; Therapeutic Use
  • Acronyms ORION-5
  • Sponsors The Medicines Company
  • Most Recent Events

    • 06 Nov 2017 According to The Medicines Company media release, the phase III program for inclisiran comprises four trials ORION-5, ORION-9, ORION-10 and ORION-11. The data from these trials will support the submission of a New Drug Application (NDA) in the United States and a Marketing Authorization Application (MAA) in the European Union at or around the end of 2019. This trial is expected to begin before the end of 2017.
    • 30 Aug 2017 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top